Ascletis Announces FDA Clearance for ASC50 Psoriasis Trial
ASC50 is an in-house discovered and developed oral small molecule interleukin-17 (IL-17) inhibitor for the treatment of multiple autoimmune and inflammatory diseases, including psoriasis. Following...